Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | METAP2 | P50579 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 4/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1905418 | 0.99 | SMN1; SMN2 (0.50) | SMN1; SMN2METAP2GAATERTPTK2 | |
| Water SCHEMBL1905420 | 0.99 | SMN1; SMN2 (0.50) | SMN1; SMN2METAP2GAATERTPTK2 | |
| SCHEMBL13856862 | 0.88 | CYP1A2 (0.54) | SMN1; SMN2METAP2GAATERTPTK2 | |
| SCHEMBL12325293 | 0.87 | CYP1A2 (0.49) | SMN1; SMN2METAP2GAATERTPTK2 | |
| SCHEMBL14027400 | 0.86 | NPC1 (0.54) | SMN1; SMN2CYP3A4CYP2C9LMNAMEN1 | |
| SCHEMBL3083631 | 0.81 | MAPT (0.59) | SMN1; SMN2CYP3A4CYP2C9LMNAMEN1 | |
| SCHEMBL13856857 | 0.79 | TP53 (0.61) | PTK2CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL3071327 | 0.75 | LMNA (0.60) | SMN1; SMN2LMNAKDM4EALDH1A1NPSR1 | |
| SCHEMBL7746877 | 0.72 | MAPT (0.50) | SMN1; SMN2LMNAALDH1A1NPSR1HTT | |
| SCHEMBL3074301 | 0.72 | TP53 (0.53) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-6894054-B2 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | SMN1; SMN2 4868/4885METAP2 2783/4885GAA 2091/4885 |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | SLC1A2, SLC1A1, SLC1A3 | SMN1; SMN2 210/4885METAP2 662/4885GAA 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.